Xingzheng International: Shouyu Shiyao Group (01093)'s “purchase” rating of innovative products is expected to contribute to growth

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Xingzheng International released a research report stating that it covered Shiyao Group (01093) for the first time and gave it a “buy” rating. The bank expects the company's operating income from 2026 to 2028 to be $32.296 billion, and net profit to mother of $7.249 billion, $5.887 billion and $6.534 billion respectively, corresponding to the closing price on November 12, 2026, with price-earnings ratios of 13.34 times, 16.43 times and 14.81 times, respectively. The company's proprietary drug business in 2025 was dragged down by factors such as collection. In 2026, AstraZeneca (AZN.US) authorization and enbipril release led to an increase in revenue. New products such as aniturizumab are expected to continue to be released in 2027 and beyond, becoming a new performance growth point.

Xingzheng International's main views are as follows:

Performance picked up in the first half of 2026, authorized cooperation and innovative R&D to build medium- to long-term growth resilience

In the first half of 2026, the company achieved revenue of 18.594 billion yuan, an increase of 40.1% over the previous year, of which proprietary drug revenue (excluding authorized revenue) was 10.17 billion yuan, an increase of 10.8% over the previous year. The company's core product, Enbipu, continues to be deeply involved in the grassroots and out-of-hospital markets, and sales revenue achieved a significant year-on-year increase, contributing a core increase to the company's performance. Furthermore, since 2025, the company has completed 6 out-licensing transactions, with a total down payment of US$1.49 billion. In the first half of 2026, 7 key products including anitumab were launched, and 18 new key phase III clinical studies were carried out, providing a value foundation for the company's medium- to long-term growth.

In the field of anti-cancer, SYS6010 reached the main end in the Chinese phase III clinical trial of TKI treated EGFR mutant NSCLC. SYS6090 showed initial anti-tumor activity, and continued to advance in many innovative fields such as in vivo CAR-T and tumor vaccines

The company has developed diverse innovative anti-tumor molecules based on multiple differentiated engineering optimization techniques and novel pharmacological solutions. Among them, SYS6010 reached the main PFS endpoint in SYNSTAR-01, the phase III clinical trial of TKI treated EGFR mutant NSCLC, and achieved MPFS 7.6 months and MoS 19.4 months in people treated with TKI and platinum-containing chemotherapy. In addition, the company's IO 2.0 molecule SYS6090 showed initial antitumor activity in treated HCC and CRC. Phase II clinical studies have been registered on AGA- NSCLC 1L+, and 3 clinical trials with combined ADCs have begun. In terms of CAR-T, the company has mastered LV and LNP delivery carrier technology. Among them, SYS6055 is the first clinically approved in vivo CAR-T in China, and has BD prospects. In terms of mRNA cancer vaccines, the company's 3 tumor therapeutic mRNA vaccines, including SYS6026, SYS6006, and SYS6077, have been clinically approved or entered into clinical research. Of these, 2 are general-purpose, and there is great potential for use in combination with IO.

In the field of non-oncology, focusing on the long-term efficacy of GLP-1, intrahepatic and extra-hepatic delivery of siRNA, and continuous enhancement of innovative value

The company's long-term sustained release platform and peptide drug AI discovery platform reached a BD with a potential transaction amount of 18.5 billion US dollars with AZ. Its GLP-1 long-acting molecule optimizes the PK curve through technical means such as prescription optimization and molecular engineering, and supports monthly dosage targets. siRNA has a layout for both intrahepatic and extra-hepatic delivery. Among them, the GalNAc ligand, which relies on intrahepatic delivery, replaces L96 classical trigeminal stent coupling through a linear tandem structure, effectively reducing production costs; in terms of extra-hepatic delivery, the company has arranged multiple extrachepatic tissues such as kidney, eye, CNS, and fat. Among them, the kidney has reached a potential BD of 1.77 billion US dollars with AZ. Other hepatic tissues have verified the differentiated path of 2′-S lipophilic nucleoside modification, which has further potential for BD.

Risk Alerts

The risk of failure in the development of new drugs, the risk that clinical progress and approval times fall short of expectations, the risk of price declines exceeding expectations, and the risk of increased market competition.